ranitidine Articles
Mylan debuts generic Antara; FDA approves generics of Actavis' Suboxone, Lupin's Suprax and Zydus' Zantac
25 February 2013
Americans with heartburn paying too much for Nexium's 'Purple Pill,' claims Consumer Reports
30 October 2009
Four drugmakers to pay $124 million for submission of false claims to USA’s Medicaid
20 October 2009
Japan stock market week to May 25, 2009
27 May 2009
GSK drops Japanese partner for Zantac
28 April 2008
CVS pays c$37M to settle US Rx case
31 March 2008
Headlines 25 years ago this week....
26 November 2007
Japanese generic drug listings for November
21 November 2007
Headlines 25 years ago this week....
19 November 2007
Headlines 25 years ago this week....
15 October 2007
Boeh Ing's 1st half 2007 sales up 2.1%
6 August 2007
Headlines 25 years ago this week....
2 July 2007
Headlines 25 years ago this week....
28 May 2007
Headlines 25 years ago this week....
8 January 2007
Boeh Ing buys J&J/Pfizer's OTC Zantac
23 October 2006
GSK pays $3.1 billion to settle transfer pricing tax dispute with US IRS
18 September 2006
Headlines 25 years ago this week....
11 September 2006
J&J wins bidding war for Pfizer
3 July 2006
25 years ago this week....
16 January 2006
Georgia Medicaid saves $20M by controlling PPIs
24 January 2005
GSK acts against generic marketers of Zantac in Israel
16 February 2004
Drugs
2 June 2003
Francisco Durban moving into generics
5 August 2002
GSK faces US tax evasion charges
17 June 2002
Indian bulk drug price moves boost MNCs
11 February 2002
Galapagos Genomics and Euroscreen sign GPCR deal
12 December 2001
French price cuts for GSK, Lilly, Merck drugs
16 August 2001
PhRMA R&D spending claims attacked
25 July 2001
India cuts prices of five bulk drugs
13 March 2001
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Glaxo Wellcome Jan-Oct trading results see sales up 6%
17 November 1999
Vanguard & Menarini sign frovatriptan deal
15 September 1999
Stock Commentary Tokyo
19 August 1999
GW struggles to post FY double-digit growth
27 July 1999
Generic approvals for Norton in UK
1 July 1999
Pediatric study exclusivity "windfalls"
30 March 1999
Stock Commentary Europe
25 February 1999
GW fully absorbs Zantac patent loss
18 February 1999
FDA approves another generic Zantac
4 February 1999
Indian patent bill OKed by upper house
27 January 1999
GW, W-L dissolve OTC JV
5 January 1999
Glaxo India Withdraws Writ Against Ranitidine
8 December 1998
HMO Stops Supplying Zantac, Xanax, Mevacor
8 December 1998
GW Steering Clear Of Pharma Merger Mania
2 December 1998
GW 10-Month Sales Fail To Excite
19 November 1998
New Product Cycle For Glaxo Wellcome
28 October 1998
Rx-To-OTC Switches "Not Working Except In USA"
6 October 1998
GW's Dutch Pharmacy Deals Under Scrutiny
1 October 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
Stock Commentary Europe
6 August 1998
GW & W-L Dissolve OTC Joint Venture
5 August 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Pharmaceutical Companies Face Up To The Future
15 June 1998
JP Morgan Upgrades GW To Buy
15 May 1998
Alliance UniChem Profits Up, Spending Cuts Warned
21 April 1998
Changing Scene For Drugmakers In USA
14 April 1998
Rx Drug Sales In USA Grew 12.6% Last Year
6 April 1998
Trading Margins To Fall At GW
2 April 1998
GW's Abacavir In Expanded-Access
19 March 1998
Ranbaxy Launches Generic Ranitidine In USA
16 March 1998
FDA Clears GW's Effervescent Zantac
5 March 1998
Correction: GW Results
26 February 1998
Glaxo Wellcome Profits Hit By Strength Of Sterling
19 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Greece To Slim Official Drug List
4 February 1998
Yamanouchi Looks For Gaster Successor
22 January 1998
Drug Cos Must Act Now To Ensure Future Prosperity
22 January 1998
Knoll's High Hopes For Its Obesity Drug Sibutramine
15 January 1998
Australia Excludes SSRIs From Final TGP Scheme
17 December 1997
FDA Stance At Conflict With Court Ruling On Generic Exclusivity
2 December 1997
3rd-Qtr Rx Drug Prices Up 2.9%, Generics Fall 6.4%
25 November 1997
Glaxo Wellcome Still Plagued By Strong Sterling
20 November 1997
Glaxo Wellcome Assesses Zantac Generic Competition
10 November 1997
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
